Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 57Carcinoma, Hepatocellular 45Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Lung Neoplasms 10Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Esophageal Neoplasms 9Advanced Gastric Cancer 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Liver Neoplasms 5Glioma 5Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

camrelizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Cancer Recurrent × apatinib × Clear all
NCT04067986 2020-09-29

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Zhongshan Hospital Xiamen University

Phase 1/2 Unknown
62 enrolled
Gastrointestinal

Colorectal Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡